300158 振东制药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,096,513-24.74%2,783,0592,971,1283,626,0163,728,555
减:营业总成本1,174,523-19.54%3,109,1383,381,8813,777,4323,922,192
    其中:营业成本514,226-27.75%1,389,9451,560,1251,799,4161,889,842
               财务费用3,33857,196.57%1,417(1,210)(9,566)9,988
               资产减值损失(25,569)185.77%658(294,073)(36,242)(5,253)
公允价值变动收益252-81.04%1,586(139,440)1,95811,591
投资收益331-94.92%10,78241,97343,08254,459
    其中:对联营企业和合营企业的投资收益42-108.36%--------
营业利润(93,910)-453.85%(264,938)(714,707)(29,983)(5,920)
利润总额(97,140)-564.54%(277,623)(1,315,022)(37,693)(5,280)
减:所得税费用(1,838)-112.76%25,46417,91710,17751,718
净利润(95,302)-1,565.37%(303,087)(1,332,939)(47,869)(56,999)
减:非控股权益(2,576)80.46%(2,025)(4,375)(3,885)(5,709)
股东净利润(92,725)-1,269.11%(301,062)(1,328,564)(43,984)(51,290)

市场价值指针
每股收益 (元) *-0.093-1,312.99%-0.300-1.298-0.043-0.050
每股派息 (元) *------------
每股净资产 (元) *3.282-9.76%3.3753.6785.0405.114
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容